News & Updates

Made-in-Canada coronavirus vaccine starts human clinical trials

01/29/2021

Excerpt from the Article: A made-in-Canada vaccine to protect against COVID-19 began human clinical trials Tuesday in Toronto, says the biotechnology company that developed the vaccine. Toronto-based Providence Therapeutics said three shots will be given to 60 adult volunteers at a clinical trial site in Toronto in the first phase of the trial on Tuesday.  Fifteen of…

Read More

A closer look at T cells reveals big differences in mild vs. severe COVID-19 cases

01/29/2021

Excerpt from the Article: LA JOLLA, CA—A big question on people’s minds these days: how long does immunity to SARS-CoV-2 last following infection? Now a research team from La Jolla Institute for Immunology (LJI), The University of Liverpool and the University of Southampton has uncovered an interesting clue. Their new study suggests that people with…

Read More

Patients in Cancer Remission at High Risk for Severe COVID-19 Illness

01/28/2021

Excerpt from the Press Release: PHILADELPHIA—Patients with inactive cancer and not currently undergoing treatments also face a significantly higher risk of severe illness from COVID-19, a new study from Penn Medicine published online today in JNCI Cancer Spectrum shows. Past reports have established an increased risk of severe disease and death for sick or hospitalized…

Read More

Ask Us Anything In Clinical Research – 2021 Life Sciences Business Development & Marketing Strategies

01/28/2021

On January 21st, we held our first Ask Us Anything in Clinical Research Virtual networking meeting for the new year! Heather and I were joined by our guest speaker, Pearl Mensah of Pilatus Comparator Solutions for this exciting meeting. We’ve had 10 months of experience marketing and selling remotely. We’ve seen what worked, and what’s…

Read More

Low-Dose CT Lung Screening Gets Boost from AI

01/27/2021

Excerpt from the Article: It is possible to increase the specificity of low-dose CT (LDCT) lung cancer screening programs without chipping away at sensitivity – all it takes is folding artificial intelligence (AI) in with Lung-RADS. That capability is based on the development of a lung nodule management system, created by investigators from the University…

Read More

CHOP Researchers Receive Funding to Study Effects of COVID-19 on Preterm Birth

01/27/2021

Excerpt from the article: Researchers at Children’s Hospital of Philadelphia (CHOP) have formed a new consortium that will study the effects of the COVID-19 pandemic on preterm birth and prenatal care, funded by $300,000 in grants from the Independence Blue Cross Foundation, Highmark Blue Cross Blue Shield Delaware’s donor-advised fund, and BluePrints for the Community.…

Read More

Download the FDAs Action Plan on “Artificial Intelligence/Machine Learning (AI/ML)- Software as a Medical Device (SaMD)”

01/26/2021

The FDA has released a new Action Plan on Artificial Intelligence/Machine Learning (AI/ML)- Software as a Medical Device (SaMD). You can download it below by clicking the button! Download The Action Plan

Read More

Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19

01/26/2021

Excerpt from the Press Release: SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA followed a Pre-IND meeting with…

Read More

Quebec researchers say they have found an effective drug to fight COVID-19

01/25/2021

Excerpt from the Press Release: MONTREAL — A team of researchers from the Montreal Heart Institute believe they have found an effective weapon against COVID-19: colchicine, an oral tablet already known and used for other diseases. For Dr. Jean-Claude Tardif, who led the study, this is a “major scientific discovery,” he said. Colchicine is the…

Read More

Prosetta Biosciences Announces Novel Solution to COVID-19 Crisis

01/25/2021

Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Prosetta Biosciences, a San Francisco biotechnology company, has developed novel small-molecule drugs that research indicates are effective not only against the COVID-19 virus, but against other virus families that cause respiratory disease, including influenza and the common cold – without the liability of drug resistance development. The compounds…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives